Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and feasibility of the company's Fortitude Sirolimus-Eluting Bioresorbable Scaffold in patients with symptomatic coronary artery disease.

Medtronic Inc. announced the U.S. launch of the SEEQ Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. Medtronic completed the acquisition of U.S.-based Corventis Inc., which developed the technology, in June 2014.

Occlutech  announced that it has obtained a European CE mark approval for its dedicated Paravalvular Leak Closure Device (PLD).

The ASE Education and Research Foundation hosted a one-day event, Value-Based Healthcare: Summit 2014, Sept. 12 in Washington, D.C., which gathered thought leaders from across the healthcare spectrum to discuss cardiac imaging in the new value-based healthcare paradigm. The Summit culminated with the announcement that the ASE Foundation’s largest research grant in its history, a $200,000 multi-year grant, has been awarded to a research team from the University of Chicago led by Victor Mor-Avi, Ph.D., FASE, director of cardiac imaging research. 

St. Vincent Heart Center officials announced that the faith-based hospital is the second in the nation to implant the new investigational “heart pump.”

Ekos for PE
Ekos for PE
Ekos for PE

Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the clinician with a quandary. With a 3 percent mortality rate[1] — just shy of the mortality rate of acute myocardial infarction — acute intermediate-risk PE warrants therapy that will rapidly reduce right ventricular strain and pulmonary artery pressure. Systemic lytics, with a 2 to 3 percent[2] risk of catastrophic intracranial bleeding, has a major complication rate equal to the overall mortality of the disease. Yet standard anticoagulation often acts too slowly, achieving full efficacy in responsive patients over the course of weeks or even months. In fact, the recent PEITHO trial demonstrated a 5 percent need for rescue thrombolysis among patients receiving anticoagulation alone.

In the September issue of the Journal of the American Society of Echocardiography is the article "Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.” These recommendations include echocardiographic assessment and monitoring of the left ventricle (LV) using ejection fraction (EF) and strain imaging, along with right ventricle (RV) using TAPSE, S’ and FAC for improved management of oncology patients at risk for cardiotoxicity. All these capabilities are provided in EchoInsight visualization and analysis in a workflow-enhancing, vendor-neutral software platform.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now